115 filings
Page 5 of 6
6-K
zhrdnql rgrw3mftz7
19 Sep 22
Report of Foreign Private Issuer
9:38pm
6-K
3t0n9y8a6 ad2m
8 Sep 22
Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference
6:04am
6-K
yo9k1g k7sonl0j59
6 Sep 22
Incannex Included in the S&P/ASX 300 Index
6:01am
6-K
ey3plq9 2en29
1 Sep 22
Report of Foreign Private Issuer
6:13am
6-K
oercn6
17 Aug 22
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors
6:04am
6-K
yyyzsr7xf6mco7b
9 Aug 22
Report of Foreign Private Issuer
6:01am
6-K
nbs cqvvklamr5c745o
4 Aug 22
Report of Foreign Private Issuer
8:32pm
6-K
vz8abo dz
2 Aug 22
Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A
6:06am
6-K
dyz 8sqwlbl5pq
28 Jul 22
Incannex Healthcare Quarterly Activities Report and Appendix 4C
2:35pm
6-K
lozuv6289k
21 Jul 22
Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A
6:02am
6-K
nt0v8j9fc5oa0 1xqz65
28 Jun 22
Report of Foreign Private Issuer
6:52pm
6-K
vdkpff
3 Jun 22
Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
6:02am
6-K
dze1xyfa84bshs4 q2
16 May 22
Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea
9:50pm
6-K
8ho ldsx8uxlv0j
12 May 22
Report of Foreign Private Issuer
9:25am
6-K
8ajuw2f7y5ox98vb5 zs
28 Apr 22
Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:40am
6-K
rnexc
4 Apr 22
Incannex to Acquire APIRx Pharmaceuticals USA, LLC
6:07am
6-K
17m7h0m lf
21 Mar 22
Report of Foreign Private Issuer
6:03am
EFFECT
mww9ycs5unr
28 Feb 22
Notice of effectiveness
12:15am
SEC STAFF ACTION
ro611n4
25 Feb 22
SEC staff action: Order
9:28am
CERT
z0v2cwqzp
24 Feb 22
Certification of approval for exchange listing
3:54pm